The MMP-2 rs2285053 variant allele significantly increased overall bladder cancer risk (OR 1.33), while the rs243865 variant elevated risk specifically in younger individuals and smokers.
Case-Control (n=750)
No
Do MMP-2 rs243865 and rs2285053 polymorphisms influence bladder cancer risk in a Taiwanese population?
MMP-2 rs2285053 and rs243865 polymorphisms may influence bladder cancer susceptibility and aggressiveness, particularly interacting with age and smoking.
Effect estimate: OR 1.33 (95% CI 1.04-1.69)
p-value: p=0.0263
MMP-2 rs2285053 and, to a lesser extent, rs243865 polymorphisms may influence BLCA susceptibility and aggressiveness, particularly in the context of age and smoking. These variants may serve as potential biomarkers for personalized risk assessment, pending validation in larger, multiethnic cohorts.
LIAO et al. (Fri,) conducted a case-control in Bladder cancer (n=750). MMP-2 rs243865 and rs2285053 polymorphisms vs. Wild-type genotypes / Cancer-free controls was evaluated on Overall bladder cancer risk (OR 1.33, 95% CI 1.04-1.69, p=0.0263). The MMP-2 rs2285053 variant allele significantly increased overall bladder cancer risk (OR 1.33), while the rs243865 variant elevated risk specifically in younger individuals and smokers.